We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+4.88%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$39.2M
AUM Growth
-$20.3M
Cap. Flow
-$13.3M
Cap. Flow %
-33.9%
Top 10 Hldgs %
72.38%
Holding
26
New
–
Increased
4
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
YARW
Yarrow Bioscience
YARW
+$1.6M
2
SPXU icon
ProShares UltraPro Short S&P 500
SPXU
+$1.52M
3
WBA
Walgreens Boots Alliance
WBA
+$1.06M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.35M
2
LH icon
Labcorp
LH
+$3.16M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$2.69M
4
ABBV icon
AbbVie
ABBV
+$2.2M
5
MCK icon
McKesson
MCK
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 78.57%
2 Miscellaneous 18.89%
3 Consumer Staples 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
1
GSK
GSK
$101B
$4.08M 10.41%
80,000
– –
GILD icon
2
Gilead Sciences
GILD
$185B
$3.85M 9.82%
50,000
– –
SPXU icon
3
ProShares UltraPro Short S&P 500
SPXU
$384M
$2.95M 7.53%
2,500
+1,000
+67% +$1.52M
YARW
4
Yarrow Bioscience
YARW
$104M
$2.94M 7.51%
472
+236
+100% +$1.6M
TYME
5
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$2.89M 7.39%
2,175,000
– –
CAH icon
6
Cardinal Health
CAH
$54.6B
$2.61M 6.66%
50,000
-25,000
-33% -$1.29M
ABBV icon
7
AbbVie
ABBV
$456B
$2.46M 6.27%
25,000
-25,000
-50% -$2.2M
SPXU icon
8
CALL
ProShares UltraPro Short S&P 500
SPXU
$384M
$2.36M 6.03%
2,000
+1,250
+167% +$1.9M
WBA
9
DELISTED
Walgreens Boots Alliance
WBA
$2.12M 5.41%
50,000
+25,000
+100% +$1.06M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.1M 5.35%
19,000
-11,000
-37% -$1.22M
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$1.69M 4.31%
250,000
– –
CVS icon
12
CVS Health
CVS
$119B
$1.62M 4.15%
25,000
– –
MCK icon
13
McKesson
MCK
$104B
$1.53M 3.92%
10,000
-15,000
-60% -$2.17M
COR icon
14
Cencora
COR
$61.3B
$1.51M 3.86%
15,000
-15,000
-50% -$1.38M
ATRS
15
DELISTED
Antares Pharma, Inc.
ATRS
$1.38M 3.51%
500,000
– –
GNLN icon
16
Greenlane Holdings
GNLN
$1.95M
– –
0
– –
VKTX icon
17
CALL
Viking Therapeutics
VKTX
$3.95B
$721K 1.84%
100,000
– –
AMRN
18
CALL
Amarin Corp
AMRN
$297M
$692K 1.77%
5,000
-5,000
-50% -$688K
CLVS
19
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$675K 1.72%
100,000
– –
AZN icon
20
AstraZeneca
AZN
$255B
– –
-37,500
Closed -$3.35M
BIS icon
21
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
– –
-9,375
Closed -$1.06M
GILD icon
22
CALL
Gilead Sciences
GILD
$185B
– –
-50,000
Closed -$3.74M
LH icon
23
Labcorp
LH
$27.3B
– –
-29,100
Closed -$3.16M
SPXL icon
24
CALL
Direxion Daily S&P 500 Bull 3x ETF
SPXL
$7.02B
– –
-120,000
Closed -$3.13M
ADMS
25
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-200,000
Closed -$578K
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Healthcare Value Capital held 26 positions worth $39.2M, down 34% from $59.5M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Healthcare Value Capital withdrew a net $13.3M in Q2 2020, closing 7 positions and reducing 6 holdings. Its most notable exit was AstraZeneca, an estimated $3.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Healthcare Value Capital added an estimated $1.6M to Yarrow Bioscience.

  • Healthcare Value Capital added most to Yarrow Bioscience in Q2 2020, an estimated $1.6M increase.
  • Healthcare Value Capital's biggest Q2 2020 reduction was AbbVie, cutting an estimated $2.2M.
  • Healthcare Value Capital fully exited AstraZeneca in Q2 2020, selling an estimated $3.35M.
  • Healthcare Value Capital's ten largest holdings make up 72% of its $39.2M portfolio in Q2 2020.
  • Healthcare Value Capital opened 0 new positions and closed 7 in Q2 2020.
  • Healthcare Value Capital's portfolio value fell 34% quarter-over-quarter to $39.2M.

Based on Healthcare Value Capital's 13F filing for Q2 2020, filed 14 Aug 2020.